Jay Hallinan Appointed Chief Commercial Officer of Q’Apel Medical

Q’Apel Medical (Q’Apel), a private medical device company focused on revolutionizing neurovascular interventions, announced today the appointment of seasoned medical device executive Jay Hallinan as Chief Commercial Officer.

In this role, Jay Hallinan will lead the company’s global sales and marketing organization, oversee Q’Apel’s commercial strategy and drive revenue growth across Q’Apel’s expanding product portfolio.

“I am excited to join Q’Apel at this important time as the company looks to amplify its commercial activities,” commented Hallinan. “The team has developed an impressive portfolio that uniquely addresses the needs of clinicians performing delicate neurovascular interventions. I look forward to working together to accelerate our commercial efforts and build a solid foundation for future growth.”

With over two decades in the medical device industry, Hallinan brings extensive sales and management experience. Most recently, he served as the Vice President of North America for Stryker where he was responsible for the regional sales strategy and structure, new business development, contract negotiation and market position. Prior to that position, Jay Hallinan held commercial positions of increasing responsibility within Stryker’s organization as well as leadership positions with Boston Scientific and Medtronic. He also served as CEO of Tenex Health. Hallinan is a graduate of the University of Georgia and received his M.B.A. from the McColl School of Business at Queens College.

“I am thrilled to welcome Jay to the Q’Apel team. He is a strong leader with a proven track record of commercial success which will be critical as we look to expand our portfolio and strengthen the company’s position within the neurovascular market,” commented Jodie Fam, CEO of Q’Apel Medical. “With a focused discipline on execution, Jay’s expertise will add tremendous value and makes him an ideal fit to spearhead our commercial operations.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”